Ovapuldencel-T - AiVita Biomedical

Drug Profile

Ovapuldencel-T - AiVita Biomedical

Alternative Names: AVOVA-1; Ovarian cancer stem cell therapy - NeoStem Oncology

Latest Information Update: 23 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer AiVita Biomedical; NeoStem Oncology
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Nov 2017 Phase-II clinical trials in Ovarian, Peritoneal and Fallopian tube cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02033616)
  • 23 Oct 2017 Aivita Biomedical plans a phase II trial for Ovarian, Fallopian tube or Peritoneal cancer (Late stage disease, Metastatic disease) in USA, in November 2017 (NCT02033616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top